Myasthaenia Gravis
10
4
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
20%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature
Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis
Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)
Myasthenia Gravis Foundation of America Global MG Patient Registry
The Evaluation of Belimumab in Myasthenia Gravis (MG)